We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced that the FDA has granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Trodelvy is a first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors.
The regulatory body granted accelerated approval to Trodelvy in April 2020 based on objective response rate and duration of response results in a phase 1/2 study.
The full approval expands this indication to include treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease. The approval is supported by impressive data from the late-stage ASCENT study, wherein Trodelvy demonstrated a statistically significant and clinically meaningful 57% reduction in the risk of disease worsening or death. Trodelvy also extended median overall survival (OS) to 11.8 months versus 6.9 months, representing a 49% reduction in the risk of death.
Among all patients evaluable for safety in the ASCENT study, Trodelvy had a safety profile consistent with the previously approved FDA label.
The drug is also being evaluated as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer.
The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy for metastatic TNBC in the European Union.
The acquisition of Immunomedics, Inc. in October 2020 added Trodelvy to Gilead’s oncology portfolio, which comprises cell therapies like Yescarta and Tecartus. The massive decline in sales of its HCV franchise has led the company to focus on the HIV franchise and the oncology portfolio.
Gilead’s stock has gained 12.6% in the year so far against the industry's decline of 6.7%.
While the breast cancer market has significant potential, given the widespread prevalence, competition is stiff in this space from Roche’s (RHHBY - Free Report) strong portfolio of drugs like Perjeta, Kadcyla and Tecentriq, and AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) Lynparza (olaparib).
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Shutterstock
Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy
Gilead Sciences, Inc. (GILD - Free Report) announced that the FDA has granted full approval to Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Trodelvy is a first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors.
The regulatory body granted accelerated approval to Trodelvy in April 2020 based on objective response rate and duration of response results in a phase 1/2 study.
The full approval expands this indication to include treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received two or more prior systemic therapies, at least one of them for metastatic disease.
The approval is supported by impressive data from the late-stage ASCENT study, wherein Trodelvy demonstrated a statistically significant and clinically meaningful 57% reduction in the risk of disease worsening or death. Trodelvy also extended median overall survival (OS) to 11.8 months versus 6.9 months, representing a 49% reduction in the risk of death.
Among all patients evaluable for safety in the ASCENT study, Trodelvy had a safety profile consistent with the previously approved FDA label.
The drug is also being evaluated as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer.
The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy for metastatic TNBC in the European Union.
The acquisition of Immunomedics, Inc. in October 2020 added Trodelvy to Gilead’s oncology portfolio, which comprises cell therapies like Yescarta and Tecartus. The massive decline in sales of its HCV franchise has led the company to focus on the HIV franchise and the oncology portfolio.
Gilead’s stock has gained 12.6% in the year so far against the industry's decline of 6.7%.
While the breast cancer market has significant potential, given the widespread prevalence, competition is stiff in this space from Roche’s (RHHBY - Free Report) strong portfolio of drugs like Perjeta, Kadcyla and Tecentriq, and AstraZeneca (AZN - Free Report) and Merck’s (MRK - Free Report) Lynparza (olaparib).
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>